Every pharma CI team is somewhere on the AI journey: deep into platforms, still experimenting, or leaning entirely on partners to work it out for them. Wherever they sit, one thing is clear. The budgets are not growing, but the competitive landscapes are.
We'll map the different AI journeys we're seeing across the industry, share the real ROI from our own co-developed AI monitoring platform, and look at what it means for the entire client-vendor CI business model.
The questions on the table are ones the CI community needs to answer together: should AI-driven efficiency reduce costs, or create room for greater value? Are humans even needed anymore, and if so, should they be in the loop, or out of it? Should we be using AI to replace, or to augment?
